Research Group on Inflammation
Metabolism and Organic Damage Area
The WHO estimates that cardiovascular diseases will be the main global health and socio-economic problem in the near future. Our group has long been working in the area of Immunity and Inflammation and, more precisely, in understanding the molecular and cellular mechanisms involved in endothelial dysfunction which precedes atherosclerosis development. Consequently, the main objectives of our group are: a) to elucidate new immune players and mechanisms involved in the systemic inflammation associated with different metabolic disorders as the main cause of atherosclerosis and abdominal aortic aneurysm development, b) to detect new biomarkers of cardiovascular risk and c) generate alternative therapies with potential application in the control of the metabolic inflammation. This research is carried out through collaborations with different clinical groups belonging to INCLIVA that allow us to provide new insights to disease understanding, therapeutic success and generation of patentable new drugs. Our final aim is to provide the basis for a proper traslational research and, a rapid application of our findings to the clinic. At present, inflammation and immunology are cutting edge areas in the understanding of cardiometabolic diseases, cancer and neurological disorders among other disease states.
Coordinatora
STAFF
Collaborating Researchers
José Aparicio Collado
Nurse
Technicians
Inés Descalzo Arenas
Administrative assistant
Publications
CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction. Hueso L, Marques P, Morant B, Gonzalez-Navarro H, Ortega J, Real J, Sanz M, Piqueras L. Frontiers in Endocrinology. 2023 Apr 12;14:1154158. doi: 10.3389/fendo.2023.1154158. PMID: 37124725
Metabolomic signature and molecular profile of normal and degenerated human intervertebral disc cells. Francisco V, Eldjoudi D, Gonzalez-Rodriguez M, Ruiz-Fernandez C, Cordero-Barreal A, Marques P, Sanz M, Real J, Lago F, Pino J, Farrag Y, Gualillo O. Spine Journal. 2023 Oct;23(10):1549-1562. doi: 10.1016/j.spinee.2023.06.005. PMID: 37339697
Overview of cellular and soluble mediators in systemic inflammation associated with non-alcoholic fatty liver disease. Marques P, Francisco V, Martinez-Arenas L, Carvalho-Gomes A, Domingo E, Piqueras L, Berenguer M, Sanz M. International Journal of Molecular Sciences. 2023 Jan 24;24(3):2313. doi: 10.3390/ijms24032313. PMID: 36768637
Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity. Moreno B, Hueso L, Ortega R, Benito E, Martinez Hervas S, Peiro M, Civera M, Sanz MJ, Piqueras L, Real JT. Microvascular Research. 2022 Jan;139:104254. doi: 10.1016/j.mvr.2021.104254. PMID: 34534571
Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Marques P, Domingo E, Rubio A, Martinez-Hervas S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Biomedicine & Pharmacotherapy. 2022 Jan;145:112460. doi: 10.1016/j.biopha.2021.112460. PMID: 34864314
Correction: L-selectin regulates human neutrophil transendothelial migration. Rahman I, Sánchez AC, Davies J, Rzeniewicz K, Abukscem S, Joachim J, Hoskins Green HL, Killock D, Sanz MJ, Charras G, Parsons M, Ivetic A. Journal of Cell Science. 2022 Oct 15;135(20):jcs260658. doi: 10.1242/jcs.260658. PMID: 36259426
Effect of personality on blood glucose control in patients with type 1 diabetes. Gu Hong W, Ferri J, Ampudia-Blasco F, Martin-Brufau R, Peiro M, Benito E, Martinez-Hervas S, Sanz M, Real J. Endocrinologia, Diabetes y Nutricion. 2022 Nov;69(9):677-685. doi: 10.1016/j.endien.2021.11.034. PMID: 36470643
An updated overview of e-cigarette impact on human health. Marques P, Piqueras L, Sanz MJ. Respiratory Research. 2021 May 18;22(1):151. doi: 10.1186/s12931-021-01737-5. PMID: 34006276
L-selectin regulates human neutrophil transendothelial migration. Rahman I, Collado Sanchez A, Davies J, Rzeniewicz K, Abukscem S, Joachim J, Hoskins Green H, Killock D, Sanz M, Charras G, Parsons M, Ivetic A. Journal of Cell Science. 2021 Feb 8;134(3):jcs250340. doi: 10.1242/jcs.250340. PMID: 33408247
MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor beta inducing fibrotic responses. Milara J, Ballester B, Safont M, Artigues E, Escriva J, Morcillo E, Cortijo J. Mucosal Immunology. 2021 Mar;14(2):377-388. doi: 10.1038/s41385-020-00343-w. PMID: 32887938
Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: an overview. Villarroel-Vicente C, Gutierrez-Palomo S, Ferri J, Cortes D, Cabedo N. European Journal of Medicinal Chemistry. 2021 Oct 5;221:113535. doi: 10.1016/j.ejmech.2021.113535. PMID: 33992930
Projects
Title: Modulación de la inflamación metabólica en la prevención de la patología cardiovascular: Identificación de nuevas dianas terapéuticas y desarrollo de fármacos novedosos.
Funding body: Ministerio de Ciencia e Innovación
Principal Investigator: Mª Jesús Sanz Ferrando
Duration: 2021 – 2024
Total budget: 290.400 €
Title: Una aproximación traslacional desde la clínica a la experimentación animal: Estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos
Funding body: Conselleria de Educación, Cultura y Deporte
Principal Investigator: Mª Jesús Sanz Ferrando
Duration: 2020 – 2023
Total budget: 211.736 €
Title: Modulación farmacológica de la señalización redox en remodelado de vía aérea y vascular pulmonar en modelos humano in vitro y animal in vivo relevantes en EPOC y FPI
Funding body: Ministerio de Ciencia, Innovación y Universidades
Principal Investigator: Esteban Jesús Morcillo Sánchez
Duration: 2019 – 2020
Total budget: 96.800 €
Title: Modulación farmacológica del sistema inmune como diana clave en la prevención de la enfermedad cardiovascular asociada a desordenes metabólicos. Síntesis de fármacos novedosos
Funding body: Ministerio de Economía y Competitividad
Principal Investigator: Mª Jesús Sanz Ferrando, Juan F. Ascaso Gimilio
Duration: 2018 – 2021
Total budget: 205.700 €
Title: The William Harvey International Translational Research Academy (WHRI-ACADEMY)
Funding body: European Commission. FP7 Marie Curie Actions
Principal Investigator: Márta Korbonits
Duration: 2015 – FALTA
Total budget: 6,5 million €
Title: CIBER de Enfermedades Respiratorias (CIBERES)
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Esteban Jesús Morcillo Sánchez
Duration: 2007 –
Total budget:
+ Info
Doctoral candidate: Domingo Pérez, Elena
Director(s): Sanz Ferrando, María Jesús
Date of the defense: 01/04/2023
University: University de Valencia
Title: Effect of SGLT-2 inhibition in abdominal aortic aneurysm development. Role of rora in adipose tissue inflammation associated to obesity
Doctoral candidate: Ortega Herráiz, Rebeca
Director(s): Piqueras Ruiz, Laura; Sanz Ferrando, María Jesús; Real Collado, José Tomás
Date of the defense: 21/02/2022
University: Universitat de València
Title: Chemokine axes and inflammatory status in metabolic syndrome. Effect of pcsk9 inhibitors in the systemic inflammation associated to familial hypercholesterolemia
Doctoral candidate: Gomes Marques, Patrice
Director(s): Piqueras Ruiz, Laura; Sanz Ferrando, María Jesús
Date of the defense: 07/02/2020
University: Universitat de València
Title: Study of the systemic inflammation associated to primary hypercholesterolemia, its modulation and its impact in atherosclerosis. Role of cxcl16/cxcr6 axis in abdominal aortic aneurysm formation
Doctoral candidate: Collado Sánchez, Aida
Director(s): Sanz Ferrando, María Jesús; Piqueras Ruiz, Laura
Date of the defense: 22/07/2019
University: Universitat de València